The Global Health Body Sounds Concern Over Acute Shortage of Obesity Medications

Less than a tenth of patients eligible to benefit from GLP-1 drugs including Wegovy can access them, states the World Health Organization as it releases its initial recommendations on the drugs.

With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just access to this class of drugs.

Based on forecasts, over two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidance recognises that obesity is a lifelong illness that can be treated with holistic and continuous treatment," said the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the jabs that can assist patients in reducing significant body mass, notes the body.

GLP-1 Therapy Supply Crisis

Even in the present most favorable outlook, the production of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of eligible patients, as stated by the health organization.

The guideline calls on countries and companies to expand availability, through measures including licensing agreements.

The intellectual property rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.

The Way Weight-Loss Jabs Function

GLP-1 drugs imitate a natural hormone to slow digestion, suppress the appetite and enhance feelings of fullness so users reduce food intake.

Individuals typically start to lose weight in the initial weeks of beginning the regular doses.

Research suggests users may see weight return after a year of discontinuing the treatment, when their typical hunger return.

Being carrying excess weight increases your chance for experiencing medical conditions, like diabetes, heart disease, stroke, and specific cancers.

Obesity impacts people in all nations and was linked to millions of deaths worldwide in 2024, as per the health agency.